- Home
- ALMS
ALMS
ALUMIS INC
as 12-20-2024 4:00pm EST
Stocks
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 469.0M | IPO Year: | 2024 |
| Target Price: | $29.60 | AVG Volume (30 days): | 148.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.66 - $13.53 | Next Earning Date: | 02-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ALUMIS INC News
ALMS Breaking Stock News: Dive into ALMS Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
GlobeNewswire
a month ago
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
GlobeNewswire
a month ago
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
GlobeNewswire
2 months ago
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
GlobeNewswire
3 months ago
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
GlobeNewswire
4 months ago
Alumis to Participate in Upcoming September Investor Conferences
GlobeNewswire
4 months ago
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
GlobeNewswire
5 months ago
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
Compare ALMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALMS ALUMIS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.